Deutsche Bank Aktiengesellschaft Raises Albemarle (NYSE:ALB) Price Target to $95.00

Albemarle (NYSE:ALB) had its price target hoisted by equities research analysts at Deutsche Bank Aktiengesellschaft from $74.00 to $95.00 in a report issued on Friday,MarketScreener reports. Deutsche Bank Aktiengesellschaft’s price target suggests a potential upside of 2.43% from the company’s previous close.

A number of other equities analysts have also recently weighed in on ALB. UBS Group reduced their price objective on shares of Albemarle from $89.00 to $85.00 and set a “neutral” rating for the company in a research report on Monday, October 6th. Jefferies Financial Group upped their target price on shares of Albemarle from $90.00 to $105.00 and gave the stock a “buy” rating in a report on Monday, October 6th. HSBC upped their target price on shares of Albemarle from $60.00 to $75.00 and gave the stock a “hold” rating in a report on Monday, September 22nd. Scotiabank upped their target price on shares of Albemarle from $65.00 to $70.00 and gave the stock a “sector perform” rating in a report on Friday, August 1st. Finally, JPMorgan Chase & Co. upped their target price on shares of Albemarle from $60.00 to $80.00 and gave the stock a “neutral” rating in a report on Monday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and five have given a Sell rating to the stock. According to MarketBeat, Albemarle has an average rating of “Hold” and an average target price of $91.41.

Albemarle Stock Performance

NYSE:ALB opened at $92.75 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.47 and a current ratio of 2.31. The company has a fifty day moving average of $83.96 and a two-hundred day moving average of $70.09. The stock has a market capitalization of $10.91 billion, a PE ratio of -9.95 and a beta of 1.65. Albemarle has a fifty-two week low of $49.43 and a fifty-two week high of $113.91.

Albemarle (NYSE:ALB) last posted its quarterly earnings data on Wednesday, July 30th. The specialty chemicals company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.94. The company had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.23 billion. Albemarle had a negative net margin of 18.61% and a negative return on equity of 1.87%. The firm’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.04 earnings per share. Albemarle has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Albemarle will post -0.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Albemarle

Hedge funds have recently modified their holdings of the company. Hantz Financial Services Inc. grew its holdings in shares of Albemarle by 10,050.0% in the second quarter. Hantz Financial Services Inc. now owns 406 shares of the specialty chemicals company’s stock valued at $25,000 after purchasing an additional 402 shares during the period. CVA Family Office LLC grew its holdings in shares of Albemarle by 7,257.1% in the second quarter. CVA Family Office LLC now owns 515 shares of the specialty chemicals company’s stock valued at $32,000 after purchasing an additional 508 shares during the period. National Pension Service grew its holdings in shares of Albemarle by 74.5% in the first quarter. National Pension Service now owns 452 shares of the specialty chemicals company’s stock valued at $33,000 after purchasing an additional 193 shares during the period. Costello Asset Management INC purchased a new stake in shares of Albemarle in the first quarter valued at about $36,000. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Albemarle by 536.7% in the second quarter. EverSource Wealth Advisors LLC now owns 573 shares of the specialty chemicals company’s stock valued at $36,000 after purchasing an additional 483 shares during the period. Hedge funds and other institutional investors own 92.87% of the company’s stock.

About Albemarle

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.